Evidence map›Paper›PMID 33284800›Full record

ArticlePloS one2020

Assessment of antimalarial drug resistant markers in asymptomatic Plasmodium falciparum infections after 4 years of indoor residual spraying in Northern Ghana.

James L Myers-Hansen, Benjamin Abuaku, Muyiwa K Oyebola, Benedicta A Mensah, Collins Ahorlu, Michael D Wilson, Gordon Awandare, Kwadwo A Koram, Alfred Amambua Ngwa, Anita Ghansah

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Global Analysis ofMolecules (Basel, Switzerland) · 2022
    Article
  7. Review
  8. The Drug Resistance ofIranian journal of parasitology
    Review
  9. Profiling antimalarial drug-resistant haplotypes inTherapeutic advances in infectious disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

James L Myers-HansenNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.ORCID 0000-0001-7125-1673
Benjamin AbuakuNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
Muyiwa K OyebolaWest African Center for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Ghana.ORCID 0000-0002-1003-2570
Benedicta A MensahNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
Collins AhorluNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
Michael D WilsonNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
Gordon AwandareWest African Center for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Ghana.
Kwadwo A KoramNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
Alfred Amambua NgwaMedical Research Council Unit The Gambia at LSHTM, Banjul, Gambia.
Anita GhansahNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.ORCID 0000-0003-4639-1249
University of Ghana · GHMRC Unit the Gambia · GM

Funding

Wellcome TrustWellcome Trust 107740/Z/15/Z
6 · The paper itself

Abstract

backgroundDrug resistance remains a concern for malaria control and elimination. The effect of interventions on its prevalence needs to be monitored to pre-empt further selection. We assessed the prevalence of Plasmodium falciparum gene mutations associated with resistance to the antimalarial drugs: sulfadoxine-pyrimethamine (SP), chloroquine (CQ) and artemisinin combination therapy (ACTs) after the scale-up of a vector control activity that reduced transmission.

methodsA total of 400 P. falciparum isolates from children under five years were genotyped for seventeen single nucleotide polymorphisms (SNPs) in pfcrt, pfmdr1, pfdhfr, pfdhps and pfk13 genes using polymerase chain reaction (PCR) and high resolution melting (HRM) analysis. These included 80 isolates, each randomly selected from cross-sectional surveys of asymptomatic infections across 2010 (baseline), 2011, 2012, 2013 (midline: post-IRS) and 2014 (endline: post-IRS) during the peak transmission season, when IRS intervention was rolled out in Bunkpurugu Yunyoo (BY) District, Ghana. The proportions of isolates with drug resistant alleles were assessed over this period.

resultsThere were significant decreases in the prevalence of pfdhfr- I51R59N108 haplotype from 2010 to 2014, while the decline in pfdhfr/pfdhps- I51R59N108G437 during the same period was not significant. The prevalence of lumefantrine (LM), mefloquine (MQ) and amodiaquine (AQ) resistance-associated haplotypes pfmdr1-N86F184D1246 and pfmdr1-Y86Y184Y1246 showed decreasing trends (z = -2.86, P = 0.004 and z = -2.71, P = 0.007, respectively). Each of pfcrt-T76 and pfmdr1-Y86 mutant alleles also showed a declining trend in the asymptomatic reservoir, after the IRS rollout in 2014 (z = -2.87, P = 0.004 and z = -2.65, P = 0.008, respectively). Similarly, Pyrimethamine resistance mediating polymorphisms pfdhfr-N108, pfdhfr-I51 and pfdhfr-R59 also declined (z = -2.03, P = 0.042, z = -3.54, P<0.001 and z = -4.63, P<0.001, respectively), but not the sulphadoxine resistance mediating pfdhps-G437 and pfdhps-F436 (z = -0.36, P = 0.715 and z = 0.41, P = 0.684, respectively). No mutant pfk13-Y580 were detected during the study period.

conclusionThe study demonstrated declining trends in the prevalence of drug resistant mutations in asymptomatic P. falciparum infections following transmission reduction after an enhanced IRS intervention in Northern Ghana.

Indexed as

AmodiaquineAntimalarialsBiomarkers, PharmacologicalCarrier StateChild, PreschoolChloroquineDNA, ProtozoanDrug CombinationsDrug ResistanceFemaleGenotypeGhanaHumansInfantMalariaMalaria, FalciparumAmodiaquineAntimalarialsBiomarkers, PharmacologicalChloroquineDNA, ProtozoanDrug Combinationsfanasil, pyrimethamine drug combinationProtozoan ProteinsPyrimethamineSulfadoxine

Identifiers

PMID33284800
PMCPMC7721464
OpenAlexW3111257124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.